Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Συνδρομές Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Ενδείξεις και αγωγές Βρείτε θεραπευτικές ενδείξεις και αγωγές για νόσους, συμπτώματα και ιατρικές πράξεις
Γνωρίζατε ότι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα

PARSABIV Solution for injection (2019)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Parsabiv 2.5 mg solution for injection. Parsabiv 5 mg solution for injection. Parsabiv 10 mg solution for injection.

Qualitative and quantitative composition

Parsabiv 2.5 mg solution for injection: Each vial contains 2.5 mg of etelcalcetide (as hydrochloride) in 0.5 mL of solution. Each mL contains 5 mg etelcalcetide. Parsabiv 5 mg solution for injection: Each ...

Pharmaceutical form

Solution for injection. Clear colourless solution.

Therapeutic indications

Parsabiv is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy.

Posology and method of administration

Posology The recommended initial dose of etelcalcetide is 5 mg administered by bolus injection 3 times per week. Corrected serum calcium should be at or above the lower limit of the normal range prior ...

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Parsabiv should not be initiated if corrected serum calcium is less than the lower limit of the normal range ...

Special warnings and precautions for use

Hypocalcaemia Parsabiv treatment should not be initiated in patients if the corrected serum calcium is less than the lower limit of the normal range (see section 4.3). Potential manifestations of hypocalcaemia ...

Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed. There is no known risk of pharmacokinetic interaction with etelcalcetide. In vitro, etelcalcetide did not inhibit or induce CYP450 enzymes and was itself not ...

Fertility, pregnancy and lactation

Pregnancy There are no or limited amount of data from the use of etelcalcetide in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity ...

Effects on ability to drive and use machines

Parsabiv has no or negligible influence on the ability to drive and use machines. However, certain potential manifestations of hypocalcaemia may affect the ability to drive and use machines (see section ...

Undesirable effects

Summary of safety profile Very common side effects with Parsabiv are blood calcium decreased, muscle spasms, diarrhoea, nausea, and vomiting. They were mild to moderate in severity and transient in nature ...

Overdose

Overdose of etelcalcetide may lead to hypocalcaemia with or without clinical symptoms and may require treatment. In the event of overdose, serum calcium should be checked and patients should be monitored ...

Pharmacodynamic properties

Pharmacotherapeutic group: Calcium homeostasis, anti-parathyroid agents ATC code: H05BX04 Mechanism of action The calcium-sensing receptor on the surface of the chief cell of the parathyroid gland is the ...

Pharmacokinetic properties

Distribution In the population pharmacokinetics model, volume of distribution at steady-state was approximately 796 L. Etelcalcetide is predominately bound to plasma albumin by reversible covalent binding. ...

Preclinical safety data

The expected pharmacological effect of decreased PTH and calcium in blood were observed in animal studies at clinical exposure levels. Reductions in serum calcium associated with tremoring, convulsions ...

List of excipients

Sodium chloride Succinic acid Water for injections Hydrochloric acid (for pH adjustment) Sodium hydroxide (for pH adjustment)

Incompatibilities

This medicinal product must not be mixed with other medicinal products.

Shelf life

Shelf life: 4 years. Once removed from the refrigerator: Parsabiv is stable for a maximum of 7 cumulative days if stored in the original carton. No special temperature storage requirements are needed. ...

Special precautions for storage

Store in a refrigerator (2°C–8°C). Keep the vial in the outer carton in order to protect from light.

Nature and contents of container

Parsabiv 2.5 mg solution for injection: Single use vial (type I glass) with stopper (fluoropolymer laminated elastomeric) and an aluminium seal with flip-off dust cover. Each vial contains 0.5 mL solution ...

Special precautions for disposal and other handling

For single use only. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Marketing authorization holder

Amgen Europe B.V., Minervum 7061, 4817 ZK, Breda, The Netherlands

Marketing authorization number(s)

Parsabiv 2.5 mg solution for injection: EU/1/16/1142/001 1 vial EU/1/16/1142/002 6 vials EU/1/16/1142/003 12 vials EU/1/16/1142/004 42 vials Parsabiv 5 mg solution for injection: EU/1/16/1142/005 ...

Date of first authorization / renewal of the authorization

Date of first authorisation: 11 November 2016

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:

Μπορείτε να υποστηρίξετε τον Γαληνό στην αποστολή του να παρέχει δωρεάν έγκυρη πληροφόρηση για κάθε φάρμακο απενεργοποιώντας το Ad Blocker για αυτόν τον ιστότοπο.